Gilead appoints Sanofi official Dietmar Berger as next chief medical officer
Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent ...
Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
At the HIV Analyst & Investor Event on Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) revealed that it is developing a ...
FierceBiotech7h
Gilead's Daniel O'Day relishes Dietmar Berger reunion as cancer specialist agrees to join from Sanofi
Berger specialized in cancer long before joining Genentech, holding oncology global clinical development roles at Amgen and ...
The Pharma Letter4h
Gilead Sciences names new CMO
US antivirals major Gilead Sciences announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief ...
FiercePharma1h
EMA backs Merck’s Welireg, Bayer’s ATTR med and Gilead’s liver drug from $4.3B deal
Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...
FiercePharma22h
ICER calls out Gilead, J&J, Novartis and more in latest report on 'unsupported' price increases
In the Institute for Clinical and Economic Review’s (ICER’s) annual price-hike report, the U.S. | The U.S. watchdog is taking ...
BioSpace1h
Drug Price Watchdog Calls Out Five Pharmas for Unjustified Price Hikes
The Institute for Clinical and Economic Review flagged five drugs whose prices were raised in 2023 with no evidence to ...
Gilead gets positive EU regulatory opinion for seladelpar
Gilead Sciences (NASDAQ:GILD) has received a positive recommendation for approval from European regulators for its drug ...
Gilead Gets Key European Backing for Liver-Disease Treatment
The U.S. Food and Drug Administration in August granted accelerated approval to seladelpar, which the Foster City, Calif., company markets as Livdelzi. The drug was the key asset in Gilead's $4.3 ...
Gilead appoints Dietmar Berger as Chief Medical Officer
Gilead (GILD) announced that Dietmar Berger will join the company on January 2, 2025, as Chief Medical Officer and will become a member of ...
Business Insider9h
Gilead Sciences Says Seladelpar Gets Positive CHMP Opinion For Primary Biliary Cholangitis
(RTTNews) - Gilead Sciences, Inc. (GILD) announced Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending ...